Abstract. We have previously demonstrated that a low dose of live myeloma FO cells induced a cellular immunity against tumor without additional modulating factors. In the present study, lyophilized myeloma FO cells were used to induce anti-tumor immunity. In a myeloma vaccination model, immunization with lyophilized myeloma FO cells alone induced a slight response. However, the immunity was dramatically enhanced by myeloma FO cells transfected with a recombinant adenovirus, Adv-1/GM-CSF. The immunocytochemical staining of Adv-1/GM-CSF transfected myeloma FO cells confirmed that more than 90% of cells were positive with GM-CSF expression. Results of sandwich ELISA showed the amount of secreted GM-CSF was 240 ng/24 h per 10 6 cells. Immunization with lyophilized myeloma FO cells secreting GM-CSF prevented the tumor growth in 60% of BALB/c mice. Antibodies against myeloma FO cells were found in the sera of immunized mice. Tumor-specific T-cell response was also evaluated using cytotoxic T lymphocyte assay. In conclusion, lyophilized myeloma FO cells secreting GM-CSF can be used as a potent vaccine to induce strong and protective anti-tumor immunity.
Introduction
Based on the discovery of oncogenes (1) , it has been accepted that tumor cells derive from normal tissues. Tumorigenesis comprises a number of cascade events, which decrease the immunogenicity of tumor cells to avoid the immune surveillance from their hosts (2) . However, tumor-specific antigens or tumor-associated antigens also emerged during the course of tumorigenesis (3) (4) (5) (6) . They provided the potential targets for immunotherapy against cancer.
Multiple strategies have been attempted to evoke anti-tumor immunity. Both humoral and cellular immunity demonstrated their therapeutic potentials (7, 8) . A number of tumor antigens have been identified, such as MART-1, gp100 and TRP-2 (3, 5, 6) . Tumor cell surface antigens, such as CD20 on malignant B lymphomas and CD33 on leukemic blasts, were then used to induce tumor-specific antibodies, respectively (9) . Her2-specific antibody, Herceptin, was a prominent example in the treatment of Her2-overexpressing metastatic breast cancer (10) . Modified tumor cells, tumor peptide pulsed dendritic cells and tumor-dendritic fusion cells could also evoke immunity against cancer (11) (12) (13) . Transfected tumor cells expressed costimulatory molecules, while dendritic cells presented tumor antigens by pulsing or cell fusion. Tumor-specific cytotoxic T lymphocytes (CTL) were usually activated in these strategies. Additionally, cytokines have demonstrated their helpful effects to anti-tumor immune responses. IL-2 and IL-12 have shown their therapeutic effects in clinical applications (14, 15) , while reengineered tumor cells with GM-CSF increased the immunogenicity of irradiated tumor cells (16) . In these methods, lymphocytes were recruited and activated by these cytokines. These studies suggested that anti-tumor immunity could be induced by different methods and play roles via different mechanisms.
We have demonstrated that a low dose of live myeloma FO cells induced protective anti-tumor immunity without any additional immune modulating factors (17) . The method elicited a potent CTL response, which prevented tumorigenesis from challenge with 1x10 6 myeloma FO cells. In the present study, we investigated whether lyophilized GM-CSF secreting FO could also induce a protective anti-tumor immunity. Our data suggested that the immunity induced by lyophilized myeloma was dramatically enhanced by reengineering tumor cells to express GM-CSF. The mechanism of the anti-tumor immunity has been also studied.
Materials and methods
Mice and cell lines. Female BALB/c mice aged 6-8 weeks were purchased from the Shanghai Laboratory Animal Center. All procedures in animal experiments were approved by the Animal Study Committee, Institute of Molecular Medicine, Nanjing University. BALB/c myeloma cell line FO was obtained from ATCC. FO cells were maintained in RPMI-1640 medium (Gibco, Grand Island, NY) supplemented with 10% heat-inactivated newborn calf serum (NCS) (Gibco), ONCOLOGY REPORTS 17: 129-133, 2007 Induction of anti-tumor immunity by lyophilized myeloma cells secreting GM-CSF 2 mM L-glutamine (Hyclone, Logan, UT), 2 mg/ml sodium bicarbonate (Amersco, Cleveland, OH), 25 mM HEPES (Promega, Madison, WI), 100 U/ml penicillin (North China Pharmaceutical Group, Shijiazhuang, P.R. China) and 100 μg/ ml streptomycin (Lu-Kang Pharmaceuticals, Jining, P.R. China). Freshly isolated T-cells from mice spleen were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS) (Gibco), 50 U/ml recombinant human interleukin 2 (IL-2) (Four Rings Biopharmaceuticals, Beijing, P.R. China), 5 μg/ml concanavalin A (Promega), 2 mM L-glutamine, 2 mg/ml sodium bicarbonate, 25 mM HEPES, 100 U/ml penicillin and 100 μg/ml streptomycin.
Transfection of myeloma FO cells with recombinant adenovirus
Adv-1/GM-CSF. FO cells were incubated with recombinant adenovirus containing GM-CSF (Adv-1/GM-CSF) (Institute of Molecular Medicine, Nanjing University, P.R. China), which was diluted 10 times by RPMI-1640 without serum, at 37˚C for 1 h. FO cells transfected with Adv-1/GM-CSF were maintained in RPMI-1640 supplemented with 10% NCS for 2 days.
Lyophilization of myeloma FO cells.
Myeloma FO cells transfected with Adv-1/GM-CSF and normal myeloma FO cells were harvested and counted. Cells were washed with PBS 3 times and aliquoted to 1x10 6 per vials. After decanting the supernatant and freezing the cell pellets at -80˚C for 1 h, cells were lyophilized by using a freeze-dryer (FTS systems, Stone ridge, NY). Flow cytometry assay. Myeloma FO cells were washed by PBS and incubated by 1:100 diluted sera from the immunized and control mice. The cells were then incubated with PEconjugated goat anti-mouse antibody (BD Pharmingen). Tcells isolated from mice splenocytes were incubated with PE-conjugated anti-CD3 antibody (BD Pharmingen) to confirm the purity. All samples were analyzed with a FACS caliber (Becton Dickinson, CA).
The CTL assay. The T-cells harvested from mouse spleen by nylon wool absorption were plated into 24-well plates containing 50 μg/ml mitomycin C (Union Pharmaceuticals, Beijing, P.R. China) pre-treated FO for 72 h. The ratio of T-cells to FO cells was 5:1. T-cells were then harvested and cocultured with the target FO cells for 6 h in a 96-well Ubottom plate at various ratios. The supernatant was measured for lactate dehydrogenase (LDH) released from lysed cells using the CytoTox 96 cytotoxicity assay kit (Promega).
Percentage of specific release of LDH was determined by the following equation: percent specific release (%) = (experimental release -spontaneous T-cell release -spontaneous FO cell release) / (maximal FO cell release -spontaneous FO cell release) x100.
Statistical methods. Statistical significance was determined using Student's t-test. 90% of transfected FO cells were positive for GM-CSF secretion (Fig. 1) . Additionally, recombinant GM-CSF released in the supernatant from transfected cells was 240 ng/24 h per 10 6 cells, as quantified by a sandwich ELISA.
Results

Transfection
Anti-tumor immunity induced by lyophilized myeloma cells.
A tumor vaccination model was used to evaluate the induced anti-tumor immunity. Successful immune responses should help mice survive from the challenge of tumor cells. Female BALB/c mice were immunized biweekly with PBS, lyophilized myeloma FO and lyophilized myeloma FO secreting GM-CSF, respectively. One week after the second immunization, mice were subcutaneously injected with 1x10 6 myeloma FO cells. All control mice died within 40 days after the inoculation of FO cells. All mice immunized with lyophilized myeloma FO cells died within 51 days later. However, in the group of mice immunized with lyophilized myeloma FO cells secreting GM-CSF, 60% of mice survived without development of tumors (Fig. 2) . At the same time, tumor sizes of the tumorbearing mice in the immunized group were not obviously different from those of the control mice (Fig. 3) .
The dominant role of humoral immunity. We further investigated why lyophilized myeloma FO secreting GM-CSF induced strong anti-tumor immunity. Tumor-specific antibody response and cytotoxic T-cells against FO cells from immunized mice were assayed by FACS and CTL assay, respectively. Myeloma FO cells were incubated with diluted serum from immunized and control mice. Immune serum from mice immunized with lyophilized FO myeloma cells secreting GM-CSF demonstrated specific recognition to FO cells in comparison with the control serum (Fig. 4) , suggesting that a successful humoral immune response against myeloma FO cells was induced. Additionally, the lysis activity against FO cells of cytotoxic T lymphocytes was tested. T lymphocytes were isolated from mice splenocytes by a nylon wool fiber column. The purity of collected cells reached 78.46±8.01% (Fig. 5 ). In the CTL assay, the percentage of lysis increased along with the ratios of effector cells versus target cells. However, cytotoxicity mediated by T-cells from myeloma FO cells secreting GM-CSF immunized mice and the control mice was not dramatically different (Fig. 6 ). These data suggested that strong humoral immunity was raised in the present method, whereas the role of cellular immunity remained to be elucidated.
Discussion
In our previous study, a low dose of live myeloma FO cells induced a potent cellular immunity against tumor without foreign modulating factors, which inhibited the tumor growth in immunized BALB/c mice (17) . In the present study, we investigated whether lyophilized myeloma FO cells could also induce anti-tumor immunity alone. In the myeloma vaccination model, lyophilized myeloma FO cells did not induce a strong immunity against tumor. However, the immunity could be greatly enhanced by transfection of myeloma FO cells with Adv-1/GM-CSF, which prevented 60% of BALB/c mice from developing tumors. The mechanism of the anti-tumor immunity was also analyzed. Higher levels of antibodies in the immune serum against myeloma FO cells were detected using FACS, suggesting the humoral immune response against tumor cells was induced. In the CTL assay, there was an obvious but not dramatic difference between T-cells from myeloma FO cell expressing GM-CSF immunized mice and the control mice. These results suggested that cytotoxic T lymphocytes were also activated. In conclusion, humoral immunity played an important role in the protective immunity. It was different from the immunity induced by live cells or irradiated tumor cell secreting cytokines. This may be due to the different types of the vaccines. Cell-type vaccines could provide three signals, including antigens presented in MHC molecules, costimulatory factors and cytokines (18) . Additionally, they are arrayed in a certain dimensional form on cell membrane, which could be recognized by pattern recognition receptors (PRR) on lymphocytes (19) . Cellular immunity was then activated. However, lyophilized tumor cells were mainly in the protein types, which were lacking in costimulatory factors and special dimensional arrays. Therefore, the stronger humoral immunity was usually induced by protein vaccines, but not the cellular immunity. Only if the PRR were activated, such as pulsed dendritic cells with tumor antigens, could cellular immunity be induced (12) .
Traditionally, tumor cell lysates were prepared by sonication or freeze and thaw (20) . Protein antigens were likely to be proteolysed under these conditions. In the present method, tumor lysates were prepared by lyophilization, which prevented the possibility of proteolysis. Compared with our previous method, the present method was safer than immunization with live tumor cells and it is promising for use when developing safe and potent tumor vaccines for clinical myeloma immunotherapy. 
